{"id":11128,"date":"2023-03-05T00:00:00","date_gmt":"2023-03-05T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/isatuximab-sarclisa-les-negociations-sont-terminees\/"},"modified":"2025-08-19T08:28:12","modified_gmt":"2025-08-19T13:28:12","slug":"isatuximab-sarclisa-les-negociations-sont-terminees","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/","title":{"rendered":"Isatuximab (Sarclisa)\u202f: les n\u00e9gociations sont termin\u00e9es!"},"content":{"rendered":"<p>C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises&nbsp;:<\/p>\n<ul>\n<li>En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des patients atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant et r\u00e9fractaire qui ont re\u00e7u au moins deux traitements ant\u00e9rieurs, dont le l\u00e9nalidomide et un inhibiteur du prot\u00e9asome.<\/li>\n<li>En association avec le carfilzomib et la dexam\u00e9thasone, pour le traitement des patients adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u 1 \u00e0 3 lignes de traitement pr\u00e9alables.<\/li>\n<\/ul>\n<p>Depuis sa recommandation de remboursement positive \u00e9mise par l\u2019ACMTS en avril 2021, My\u00e9lome Canada a fait plusieurs actions de revendications aupr\u00e8s des parties prenantes afin de voir aboutir ce processus. Nous sommes tr\u00e8s heureux de voir que c\u2019est aujourd\u2019hui chose faite!<\/p>\n","protected":false},"excerpt":{"rendered":"<p>C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises&nbsp;: En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11128","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"lemieuxbedard\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Isatuximab (Sarclisa) : les n\u00e9gociations sont termin\u00e9es! | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2023-03-05T05:00:00+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2025-08-19T13:28:12+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Isatuximab (Sarclisa) : les n\u00e9gociations sont termin\u00e9es! | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#blogposting\",\"name\":\"Isatuximab (Sarclisa) : les n\\u00e9gociations sont termin\\u00e9es! | My\\u00e9lome Canada\",\"headline\":\"Isatuximab (Sarclisa)\\u202f: les n\\u00e9gociations sont termin\\u00e9es!\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2023-03-05T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:12-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement, News &amp; Events, Nouvelles de My\\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"position\":2,\"name\":\"News &amp; Events\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"position\":3,\"name\":\"What's new at Myeloma Canada\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#listItem\",\"name\":\"Isatuximab (Sarclisa)\\u202f: les n\\u00e9gociations sont termin\\u00e9es!\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/#listItem\",\"name\":\"News &amp; Events\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#listItem\",\"position\":4,\"name\":\"Isatuximab (Sarclisa)\\u202f: les n\\u00e9gociations sont termin\\u00e9es!\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/category\\\/news-events\\\/whats-new-at-myeloma-canada\\\/#listItem\",\"name\":\"What's new at Myeloma Canada\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/\",\"name\":\"lemieuxbedard\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"lemieuxbedard\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/\",\"name\":\"Isatuximab (Sarclisa) : les n\\u00e9gociations sont termin\\u00e9es! | My\\u00e9lome Canada\",\"description\":\"C\\u2019est avec joie que nous vous annon\\u00e7ons que les n\\u00e9gociations de l\\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\\u2019isatuximab (Sarclisa) sont termin\\u00e9s, apr\\u00e8s pr\\u00e8s de 10 mois d\\u2019attente. Une lettre d\\u2019intention a bel et bien \\u00e9t\\u00e9 \\u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\\u00e9thasone, pour le traitement des\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2023\\\/03\\\/05\\\/isatuximab-sarclisa-les-negociations-sont-terminees\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/lemieuxbedard\\\/#author\"},\"datePublished\":\"2023-03-05T00:00:00-05:00\",\"dateModified\":\"2025-08-19T08:28:12-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Isatuximab (Sarclisa) : les n\u00e9gociations sont termin\u00e9es! | My\u00e9lome Canada","description":"C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des","canonical_url":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#blogposting","name":"Isatuximab (Sarclisa) : les n\u00e9gociations sont termin\u00e9es! | My\u00e9lome Canada","headline":"Isatuximab (Sarclisa)\u202f: les n\u00e9gociations sont termin\u00e9es!","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2023-03-05T00:00:00-05:00","dateModified":"2025-08-19T08:28:12-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#webpage"},"articleSection":"Actualit\u00e9s et \u00e9v\u00e9nement, News &amp; Events, Nouvelles de My\u00e9lome Canada, What's new at Myeloma Canada, Facultatif, Optional"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","position":2,"name":"News &amp; Events","item":"https:\/\/myeloma.ca\/category\/news-events\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","position":3,"name":"What's new at Myeloma Canada","item":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#listItem","name":"Isatuximab (Sarclisa)\u202f: les n\u00e9gociations sont termin\u00e9es!"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/#listItem","name":"News &amp; Events"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#listItem","position":4,"name":"Isatuximab (Sarclisa)\u202f: les n\u00e9gociations sont termin\u00e9es!","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/category\/news-events\/whats-new-at-myeloma-canada\/#listItem","name":"What's new at Myeloma Canada"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/","name":"lemieuxbedard","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/46bccf9afb319784ce7a4c49e51be67f2ed9bed19ab02f5f0a63c7aba8c80f06?s=96&d=mm&r=g","width":96,"height":96,"caption":"lemieuxbedard"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/","name":"Isatuximab (Sarclisa) : les n\u00e9gociations sont termin\u00e9es! | My\u00e9lome Canada","description":"C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/lemieuxbedard\/#author"},"datePublished":"2023-03-05T00:00:00-05:00","dateModified":"2025-08-19T08:28:12-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"Isatuximab (Sarclisa) : les n\u00e9gociations sont termin\u00e9es! | My\u00e9lome Canada","og:description":"C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des","og:url":"https:\/\/myeloma.ca\/fr\/2023\/03\/05\/isatuximab-sarclisa-les-negociations-sont-terminees\/","article:published_time":"2023-03-05T05:00:00+00:00","article:modified_time":"2025-08-19T13:28:12+00:00","twitter:card":"summary_large_image","twitter:title":"Isatuximab (Sarclisa) : les n\u00e9gociations sont termin\u00e9es! | My\u00e9lome Canada","twitter:description":"C\u2019est avec joie que nous vous annon\u00e7ons que les n\u00e9gociations de l\u2019Alliance pancanadienne pharmaceutique et le manufacturier d\u2019isatuximab (Sarclisa) sont termin\u00e9s, apr\u00e8s pr\u00e8s de 10 mois d\u2019attente. Une lettre d\u2019intention a bel et bien \u00e9t\u00e9 \u00e9mise et ce pour les deux conditions soumises : En association avec le pomalidomide et la dexam\u00e9thasone, pour le traitement des"},"aioseo_meta_data":{"post_id":"11128","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-09-18 15:59:32","updated":"2026-04-30 07:11:01","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11128"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11128\/revisions"}],"predecessor-version":[{"id":31271,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11128\/revisions\/31271"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11128"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11128"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}